amcure GmbH, a biopharmaceutical company developing first-in-class cancer therapeutics, and Hinova Pharmaceuticals Inc. (Chengdu, China), one of the fastest growing start-up drug discovery and development companies in China, entered into an exclusive license agreement for AMC303 to further develop, manufacture and commercialize the peptide inhibitor in the Greater China region (Mainland China, Hong Kong SAR, Macau SAR, and Taiwan).
This text is a press release from amcure. The full text version of the article can be found here.
Maiwald Patentanwalts- und Rechtsanwaltsgesellschaft mbH acted as legal advisor to amcure. Dr Marco Stief and Dr Gisela Grabow provided the legal advisory services.
